Posts Tagged ‘Financing’

What are Allergan’s Next Steps?

What’s Allergan’s Next Steps? - OIS Podcast

The near merger between Pfizer and Allergan clearly was financially motivated. But the deal promised to bring Pfizer’s firepower to ophthalmology. What does the annulment of the deal mean for our sector? Podcast Guest Brent Saunders Dr. Gil Kliman leads the medical device investment team at InterWest Partners and invests in a broad array of…

Read More

Mixed Results Don’t Sidetrack Rhopressa Plans

Mixed Topline Results Don’t Sidetrack Rhopressa Plans - Eye on Innovation

Despite tepid investor response to safety data from the latest comparative trial of its lead-candidate glaucoma agent, Aerie Pharmaceuticals says it is still on track to file a New Drug Application for the agent in the third quarter of this year. However, investors focusing on that data, from the Rocket 1 and 2 trials, may…

Read More

What Does the Leadership Shuffle Mean for Ophthalmology?

A Look at Recent Leadership Changes in Ophthalmology - OIS Podcast

The combination of Pfizer and Allergan certainly creates some waves in ophthalmology. But did these choppy waters have anything to do with recent leadership changes in the sector? Transcript Tom Salemi: Hi, everyone, welcome back to the OIS Podcast. This is Tom Salemi, your host. Thanks a lot for joining us today. A few weeks…

Read More

Apellis IPO Road Show Takes Different Route

Putting Brakes on IPO, Apellis Lines Up Private Funding - Eye on Innovation

Putting Brakes on IPO, Apellis Lines Up Private Funding As the stock market took its 2016 nosedive, geographic atrophy drug developer Apellis Pharmaceuticals joined the parade of biotech companies that put the brakes on planned public offerings and turned back to private equity for the capital to drive their development programs. Apellis filed last fall…

Read More

Glaucoma Getting a Wake-Up Call

Glaucoma Getting a Wake-Up Call

SAN FRANCISCO — Thanks to a pending boom in minimally invasive glaucoma surgery (MIGS) devices, the global glaucoma device market is poised to come out of its long slumber and triple over the next five years, participants at the fifth annual “Glaucoma 360-New Horizons Forum” heard. Sponsored by the non-profit Glaucoma Research Foundation, the forum…

Read More

Next Few Months Important for Clearside

Next Few Months Important for Clearside

The next few months will be important for Clearside Biomedical, one of the companies pioneering drug delivery to the suprachoroidal space. The company expects by the end of this month to receive topline data from its Phase II Dogwood trial that is evaluating safety and efficacy of CLS-TA in macular edema associated with non-infectious uveitis.…

Read More

Where Will `Pfizergan’ Fit in Ophthalmology

OIS Podcast

Allergan has been a pillar of the ophthalmology sector for decades so its merger with Pfizer is a cause of concern for some. But ophthalmology leaders also see reason for optimism from the combination. The deal could bring greater firepower to ophthalmology R&D and M&A and some hope it’s a harbinger of more big players…

Read More

Protecting & Monetizing IP – A Primer for Early Stage Entrepreneurs

Protecting-&-Monetizing-IP-–-A-Primer-for-Early-Stage-Entrepreneurs

Moderator: Casey McGlynn J. Casey McGlynn formed the Life Sciences Group at Wilson Sonsini Goodrich & Rosati in 1990. It is a nationally recognized practice representing startups and emerging growth companies in the life sciences field–Medical Devices, Digital Health, Diagnostics and Biotechnology. View Full Profile Panelists: Mark S. Blumenkranz, MD Mark S. Blumenkranz, MD, MMS,…

Read More

ALPHAEON

ALPHAEON

In the world of self-pay physician services, connecting patients and providers on a broad scale has been difficult, but with the introduction of its ShoutMD platform and the launch of a direct-to-consumer ad campaign, Alphaeon Corp. is creating what CEO Robert E. Grant called “a whole ecosystem” that aims to do that and more for…

Read More